Overview of iron chelation therapy with desferrioxamine and deferiprone

Hemoglobin

Volumn 33, Issue SUPPL. 1, 2009, Pages

  Cappellini, Maria D ^a   Musallam, Khaled M ^b   Taher, Ali T ^b,c  

^a UNIVERSITY OF MILAN   (Italy)

^b AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^c Chronic Care Center Hazmieh   (Lebanon)

Author keywords

Deferiprone; Deferoxamine; Desferrioxamine; Iron chelation; Iron overload; L1

Indexed keywords

ASCORBIC ACID; DEFERIPRONE; DEFEROXAMINE; DEFEROXAMINE MESYLATE; FERRITIN; GRANULOCYTE COLONY STIMULATING FACTOR;

AGRANULOCYTOSIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTHROPATHY; BLOOD TRANSFUSION; BONE DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CONTINUOUS INFUSION; DEATH; DRUG DOSE INCREASE; DRUG MEGADOSE; ERYTHROCYTE TRANSFUSION; EYE DISEASE; FERRITIN BLOOD LEVEL; GASTROINTESTINAL DISEASE; HEARING DISORDER; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; IRON CHELATION; IRON OVERLOAD; LIVER DYSFUNCTION; LUNG DISEASE; MORBIDITY; MORTALITY; MUCORMYCOSIS; NEUTROPENIA; PANCYTOPENIA; PATIENT COMPLIANCE; PATIENT SAFETY; SEPSIS; SIDE EFFECT; TREATMENT OUTCOME; YERSINIOSIS;

CHELATION THERAPY; DEFEROXAMINE; DRUG TOXICITY; HUMANS; IRON CHELATING AGENTS; PYRIDONES; TREATMENT OUTCOME;

EID: 73949114464     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.3109/03630260903346924     Document Type: Conference Paper

References (55)

1. Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR. Thalassemia clinical research network. Complications of b-thalassemia major in North America. Blood. 2004;104:34-39.
2. Olivieri NF. The b-thalassemias. N Engl J Med. 1999;341:99-109.
3. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and disease complications in thalassemia major. Ann N Y Acad Sci. 1998;850:227-231.
4. Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol. 1996;95:26-36.
5. Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med. 1994;331:574-578.
6. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood. 1997;89:739-761.
7. Keberle H. The biochemistry of desferrioxamine and its relation to iron metabolism. Ann N Y Acad Sci. 1964;119:758-768.
8. Lee P, Mohammed N, Marshall RD, et al. Intravenous infusion pharmacokinetics of desferrioxamine and its relation to iron metabolism. Drug Metab Dispos. l993;21:640-644.
9. Marcus RE, Davies SG, Bantock HM, Underwood SR, Walton S, Huehns ER. Desferrioxamine to improve cardiac function in iron-overloaded patients with thalassemia major. Lancet. 1984;l:392-393.
10. Anderson LJ, Westwood MA, Holden S, et al. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenotis desferrioxamine: a prospective study using T2& cardiovascular magnetic resonance. Br J Haematol. 2004;127:348-355.
11. Borgna-Pignatti C, Cohen A. Evaluation of a new method of administration of the iron chelating agent deferoxamine. J Pediatr. 1997;130:86-88.
12. Harmatz P, Grady RW, Dragsten P, et al. Phase Ib clinical trial of starch-conjugated deferoxamine (40SD02): a novel long-acting iron chelator. Br J Haematol. 2007;138:374-381.
13. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89: 1187-1193.
14. Davis BA, Porter JB. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood. 2000;95:1229-1236.
15. Kontoghiorghes GJ. Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminium chelating drtigs. Toxicol Lett. 1995;80:l-18.
16. Tenenbein M, Kowalski S, Sienko A, Bowden DH, Adamson IYR. Pulmonary toxic effects of continuous desferrioxamine administration in acute iron poisoning. Lancet. 1992;l:699-701.
17. Sofroniadou K, Drossou M, Foundoulaki M, Konstantopoulos K, Kyriakou D, Zervas J. Acute bone marrow aplasia associated with intravenous administration of deferoxamine (desferrioxamine). Drug Saf. 1990;5:152-154.
18. Sharnetzky M, Konig R, Lamomek M, Tillmann W, Schroter W. Prophylaxis of systemic yersiniasis in thalassemia major. Lancet. 1984;2:79.
19. Modell B, Khan M, Darlison M. Survival in P-thalassaemia major in the UK: data from the UK register. Lancet. 2000;355:2051-2052.
20. Davis BA, O'Sullivan C, Jarritt PH, Porter JB. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood. 2004;104:263-269.
21. Cossu P, Toccafondi C, Vardeu F, et al. Iron overload and desferrioxamine chelation therapy in beta-thalassemia intermedia. Eur J Pediatr. 1981;137:267-271.
22. Pippard MJ, Weatherall DJ. Iron balance and the management of iron overload in b-thalassemia intermedia. Birth Defects Orig Artic Ser. 1988;23:29-33.
23. Kontoghiorghes GJ, Pattichis K, Neocleotis K, Kolnagou A. The design and development of deferiprone (Ll) and other iron chelators for clinical use: targeting methods and application prospects. Curr Med Chem. 2004;11:2161-2183.
24. Kontoghiorghes GJ. Ll (l,2-dimethyl-3-hydroxypyrid-4-one). Drugs Future. 1988;13:413-415.
25. Kontoghiorghes GJ, GoddardJ G, Bartlett AN, Sheppard L. Pharmacokinetic studies in humans with the oral iron chelator l,2-dimethyl-3-hydroxypyrid-4one. Clin Pharm Ther. 1990;48:255-261.
26. Kontoghiorghes GJ. New concepts of iron and altiminitim chelation therapy with oral Ll (Deferiprone) and other chelators. Analyst. 1995;120:845-851.
27. Sheppard L, Kontoghiorghes GJ. Synthesis and metabolism of Ll and other novel a-ketohydroxypyridine iron chelators and their metal complexes. Drugs Today. 1992;28:3-10.
28. Kontoghiorghes GJ, Bartlett AN, Hoffbrand AV, et al. Long term trial with the oral chelator l,2- dimethyl-3-hydroxypyrid-4-one (Ll). (I) Iron chelation and metabolic studies. Br J Haematol. 1990;76:295-300.
29. Kontoghiorghes GJ, Bartlett AN, Sheppard L, Barr J, Nortey P. Oral iron chelation therapy with deferiprone (Ll): Monitoring of biochemical, drtig and iron excretion changes. Arzn Forsch/Drug Res. 1995;45:65-69.
30. Olivieri NF, Loren G, Hermann C, et al. Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients. Lancet. 1990;336:1275-1279.
31. Collins AF, Fassos FF, Stobie S, et al. Iron balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-1 (L1) in iron-loaded patients with sickle cell disease. Blood. 1994;83:2329-2333.
32. Agarwal MB, Gupte SS, Viswanathan C, et al. Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion-dependent thalassaemia: Indian trial. Br J Haematol. 1992;82: 460-466.
33. Mourad FH, Hoffbrand AV, Sheikh-Taha M, Koussa S, Khoriaty AI, Taher A. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. Br J Haematol. 2003;121:187-189.
34. Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood. 2003;102:17-24.
35. Cohen AR. New advances in iron chelation therapy. Hematology Am Soc Hematol Educ Program. 2006;42-47.
36. Olivieri NF, Brittenham GM, Matsui D, et al. Iron-chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med. 1995;332:918-922.
37. Olivieri NF, Brittenham GM, McLaren CE, et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med. 1998;339:417-423.
38. Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood. 2003;102:1583-1587.
39. Maggio A, D'Amico GD, Morabito A, et al. Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. Blood Cell Mol Dis. 2002;28:196-208.
40. Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. Br J Haematol. 1998;103:361-364.
41. Kattamis A, Ladis V, Berdousi H, et al. Iron chelation treatment with combined therapy with deferiprone and deferioxamine: a 12-month trial. Blood Cell Mol Dis. 2006;36:21-25.
42. Olivieri NF, Koren G, Matsui D, et al. Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia. Blood. 1992;79:2741-2748.
43. Pootrakul P, Sirankapracha P, Sankote J, et al. Clinical trial of deferiprone iron chelation therapy in b-thalassaemia/haemoglobin E patients in Thailand. Br J Haematol. 2003;122:305-310.
44. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron levels and ventricular function in b thalassaemia. Lancet. 2002;360:516-520.
45. Piga A, Gaglioti C, Fogliacco E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica. 2003;88:489-496.
46. Borgna-Pignatti C, Cappellini MD, DeStefano P, et al. Cardiac morbidity and mortality in deferoxamine- or deferipronetreated patients with thalassemia major. Blood. 2006;107:3733-3737.
47. Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in betathalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006;107:3738-3744.
48. Cabantchik ZI, Breuer W, Zanninelli G, Cianciulli P. LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol. 2005;18:277-287.
49. Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo controlled, double blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassaemia major using cardiovascular magnetic resonance. Circulation. 2007;115:1876-1884.
50. Berdoukas V, Chouliaras G, Moraitis P, Zannikos K, Berdoussi E, Ladis V. The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study. J Cardiovasc Magn Reson. 2009;11:20.
51. Christoforidis A, Haritandi A, Tsatra I, Tsitourides I, Karyda S, Athanassiou-Metaxa M. Four-year evaluation of myocardial and liver iron assessed prospectively with serial MRI scans in young patients with beta-thalassaemia major: comparison between different chelation regimens. Eur J Haematol. 2007;78:52-57.
52. Perifanis V, Christoforidis A, Vlachaki E, Tsatra I, Spanos G, Athanassiou-Metaxa M. A comparison of effects of different long-term iron-chelation regimens on myocardial and hepatic iron concentrations assessed with T2& magnetic resonance imaging in patients with beta-thalassemia major. Int J Hematol. 2007;86:385-389.
53. Maggio A, Vitrano A, Capra M, et al. Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial. Br J Haematol. 2009;145:245-254.
54. Cappellini MD, Cohen A, Eleftheriou A, Piga A, Porter J, Taher A. Guidelines for the Clinical Management of Thalassaemia. 2nd rev. ed. Nicosia, Cyprus: Thalassaemia International Federation; 2008.
55. Taher A, Isma'eel H, Cappellini MD. Thalassemia intermedia: revisited. Blood Cells Mol Dis. 2006;37:12-20.